Anderson G, Bowyer F, Williams L
Thorax. 1981 Jun;36(6):462-4. doi: 10.1136/thx.36.6.462.
Forty-six patients with histologically confirmed lung cancer received treatment with the cytotoxic drug VP-16-213 in a dose of 100 mg twice daily, given orally for five days. The overall objective response rate was 11 out of 46 (24%) or 11 of the 33 (33%) who survived to receive two cycles. The drug was effective in all histological types. Only one patient developed leucopenia. This demonstration of the safety of VP-16-213 and its effectiveness suggested that this drug might be used in combination chemotherapy. A series of pilot studies showed unexplained marrow toxicity when VP-16-123 combined with vincristine was given with either methotrexate of adriamycin.
46例经组织学确诊的肺癌患者接受了细胞毒性药物VP - 16 - 213治疗，剂量为每日两次，每次100毫克，口服5天。总体客观缓解率为46例中的11例（24%），或33例存活至接受两个周期治疗患者中的11例（33%）。该药物对所有组织学类型均有效。仅1例患者出现白细胞减少。VP - 16 - 213的安全性及其有效性表明该药物可用于联合化疗。一系列初步研究表明，当VP - 16 - 123与长春新碱联合使用，同时给予甲氨蝶呤或阿霉素时，会出现无法解释的骨髓毒性。
